Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone in Young Women With NASH
NCT03576755Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Jan 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of spironolactone in Nonalcoholic steatohepatitis (NASH), sponsored by University of California, San Francisco. Started Jan 2019; status: completed.
02
Drugs
spironolactone
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03576755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576755.